VIVEbiotech and Genewity to showcase how prior knowledge can accelerate lentiviral vector process validation at CGTP Europe 2026
The presentation will explore the use of prior knowledge to support process validation for an ultra-orphan autologous cell-based gene therapy.
VIVEbiotech will be attending Cell & Gene Therapy Products (CGTP) Europe 2026, organized by CASSS and taking place at the Altis Grand Hotel in Lisbon, Portugal, from October 20 to 22, 2026.
As the cell and gene therapy field continues to advance, leveraging existing knowledge and experience can play an important role in supporting efficient development and manufacturing strategies.
As part of the event’s scientific programme, Ana Valero, PhD, Head of Technology Transfer at VIVEbiotech, together with Arjen Scholten, PhD, Senior Director CMC at Genewity, will present:
Leveraging Prior Knowledge to Accelerate Process Validation of a Lentiviral Vector for an Ultra-Orphan Autologous Cell-Based Gene Therapy.
The presentation will take place on October 20 during the plenary session Innovative Strategies and Tools to Improve CGT Development and Manufacturing.
The presentation will explore how prior knowledge can be leveraged to support process validation activities, with the aim of streamlining development pathways and accelerating progress in cell and gene therapy manufacturing.
CGTP Europe brings together experts from across the advanced therapies ecosystem to discuss scientific, technical and manufacturing advances shaping the future of the field. The event provides a platform for sharing knowledge, fostering collaboration and addressing key challenges in the development of innovative therapies.
VIVEbiotech looks forward to exchanging knowledge with industry partners, innovators and developers throughout the conference and contributing to the continued advancement of cell and gene therapies.
